Research and Development (“R&D”) Expenses: R&D expenses for the three months ended December 31, 2024, were $8.2 million, compared to $13.5 million for the same period in 2023. The decrease was due ...

In June 2024, Junshi Biosciences convened the 2023 annual general meeting, the 2024 first class meeting of A shareholders and the 2024 first class meeting of H shareholders, and completed the election ...

Gluco Extend is manufactured in the US in an FDA-approved and GMP-certified facility, ensuring safety. It can be purchased ...

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary ...

Abundant Health Physical Medicine’s unique RENEW Protocols are tailored to help patients reverse neuropathy, repair damaged ...

ProvaDent is an advanced oral probiotic complex developed to promote a clean, vibrant oral environment. The supplement fuses ...

Furthermore, its purchase and usage are entirely legal and secure. Ligan 4033 stands as a lawful and secure substitute for ...

Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”), today announced that the record date for the spin-off and distribution of shares of common stock, par value $0.0001 per share, ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by ...

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot ...

WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial ...

Unique mechanism helps reduce the frequency of bleeding episodes for people with hemophilia ...